Onconova Therapeutics Company Profile (NASDAQ:ONTX)

About Onconova Therapeutics

Onconova Therapeutics logoOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ONTX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.81
  • 50 Day Moving Average: $2.70
  • 200 Day Moving Average: $2.81
  • 52-Week Range: $2.11 - $8.17
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.85
  • P/E Growth: 0.00
  • Market Cap: $18.99M
  • Outstanding Shares: 6,759,000
  • Beta: 0.07
Profitability:
  • Net Margins: -73.67%
  • Return on Equity: -148.52%
  • Return on Assets: -50.49%
Debt:
  • Current Ratio: 3.10%
  • Quick Ratio: 3.10%
Additional Links:
Companies Related to Onconova Therapeutics:

Analyst Ratings

Consensus Ratings for Onconova Therapeutics (NASDAQ:ONTX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.50 (629.54% upside)

Analysts' Ratings History for Onconova Therapeutics (NASDAQ:ONTX)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016Maxim GroupReiterated RatingBuy$6.00View Rating Details
3/29/2016HC WainwrightReiterated RatingBuyView Rating Details
12/9/2015Piper Jaffray CompaniesReiterated RatingOverweight$60.00View Rating Details
8/28/2015Janney Montgomery ScottReiterated RatingNeutral -> Fair Value$30.00 -> $15.20View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Onconova Therapeutics (NASDAQ:ONTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
11/14/2016Q3 2016($0.82)($0.29)$1.60 million$1.70 millionViewN/AView Earnings Details
8/15/2016Q2($1.96)$2.25 millionViewN/AView Earnings Details
5/12/2016Q1($0.19)($0.27)ViewN/AView Earnings Details
3/28/2016Q4($0.27)$0.18ViewN/AView Earnings Details
11/11/2015Q3($0.32)($0.26)ViewN/AView Earnings Details
8/13/2015Q2($0.56)($0.41)ViewN/AView Earnings Details
5/14/2015Q1($0.63)($0.57)ViewN/AView Earnings Details
3/26/2015($0.71)($0.62)ViewN/AView Earnings Details
11/13/2014($0.78)($0.69)ViewN/AView Earnings Details
8/13/2014($0.89)($0.77)ViewN/AView Earnings Details
5/12/2014($0.78)($0.87)ViewN/AView Earnings Details
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details
9/6/2013Q213($5.21)$0.22 million$0.59 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Onconova Therapeutics (NASDAQ:ONTX)
Current Year EPS Consensus Estimate: $-5.91 EPS
Next Year EPS Consensus Estimate: $-3.30 EPS

Dividends

Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Onconova Therapeutics (NASDAQ:ONTX)
Insider Ownership Percentage: 27.30%
Institutional Ownership Percentage: 20.59%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.60View SEC Filing  
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.00View SEC Filing  
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.00View SEC Filing  
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.00View SEC Filing  
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Onconova Therapeutics (NASDAQ:ONTX)
DateHeadline
News IconOnconova Therapeutics Inc ONTX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ONTX)
www.bioportfolio.com - February 12 at 12:09 AM
News IconTrading Views: Watching Shares of Onconova Therapeutics Inc. (ONTX) - Davidson Register (NASDAQ:ONTX)
davidsonregister.com - February 10 at 7:59 PM
globenewswire.com logoOnconova Therapeutics, Inc. to Present at Two Investor Conferences in February - GlobeNewswire (press release) (NASDAQ:ONTX)
globenewswire.com - February 10 at 1:10 AM
finance.yahoo.com logoOnconova Therapeutics, Inc. to Present at Two Investor Conferences in February (NASDAQ:ONTX)
finance.yahoo.com - February 9 at 8:08 PM
News IconTechnical Toolbox: Investor Focus on Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - February 3 at 7:51 PM
investornewswire.com logoOnconova Therapeutics, Inc. (NASDAQ:ONTX) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:ONTX)
www.investornewswire.com - February 3 at 1:01 AM
News IconTechnical Focus: Williams %R, ADX, and CCI Levels for Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - February 1 at 1:02 AM
News IconTraders are Taking a Closer Look at These Shares: Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - January 30 at 7:42 PM
feeds.benzinga.com logoOnconova Therapeutics, Inc. to Present at NobleCON13 (NASDAQ:ONTX)
feeds.benzinga.com - January 27 at 9:34 AM
News IconRSI Review on Shares of Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - January 25 at 11:16 PM
News IconEnlivened Volatility Spotted in Shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Wall Street Beacon (NASDAQ:ONTX)
wsbeacon.com - January 25 at 11:16 PM
News IconInvestor Notebook: Focusing in on Shares of Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - January 25 at 5:50 AM
News IconWatching the Charts on Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - January 20 at 7:51 PM
News IconIndicator Level Review for Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - January 19 at 11:40 PM
News IconAmplified Volatility Spotted in Shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Wall Street Beacon (NASDAQ:ONTX)
wsbeacon.com - January 19 at 11:40 PM
News IconShare Focus: Checking the Indicators on Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - January 18 at 7:39 PM
News IconEquity Insight: Indicator Review for Onconova Therapeutics Inc. (ONTX) - Sherwood Daily (NASDAQ:ONTX)
sherwooddaily.com - January 18 at 8:50 AM
News IconCalling all Bargain Hunters: Stock Update on Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - January 18 at 8:50 AM
News IconSmall Cap Concentration on Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - January 18 at 8:50 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Wall Street Beacon (NASDAQ:ONTX)
wsbeacon.com - January 14 at 7:06 PM
finance.yahoo.com logoSeeThruEquity Initiates Coverage on Onconova Therapeutics, Inc. (NASDAQ: ONTX) with a Price Target of $5.00 (NASDAQ:ONTX)
finance.yahoo.com - January 12 at 7:40 PM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - January 10 at 8:42 AM
finance.yahoo.com logoOnconova Therapeutics, Inc. Discusses Target Indications and Clinical Development in New SNNLive Video Interview on StockNewsNow.com (NASDAQ:ONTX)
finance.yahoo.com - January 10 at 8:42 AM
finance.yahoo.com logoOnconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017 (NASDAQ:ONTX)
finance.yahoo.com - January 5 at 11:44 PM
News IconCurious Investors Should Take a Look at This Small Cap Stock: Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - January 5 at 12:53 AM
News IconPlacing This Stock in the Hotbed: Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - January 4 at 6:32 AM
News IconOnconova Therapeutics, Inc. (ONTX) Under Analyst Spotlight - UK Market News (NASDAQ:ONTX)
www.ukmarketnews.co.uk - December 28 at 9:54 AM
News IconBoom or Bust? Is there any value in Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - December 28 at 9:54 AM
News IconInvestors Swarm in on Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - December 28 at 9:54 AM
live-pr.com logoNew Market Research Report: Onconova Therapeutics, Inc. (ONTX) - Financial and Strategic SWOT Analysis Review (NASDAQ:ONTX)
www.live-pr.com - December 27 at 9:53 AM
News IconDelving into Shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - December 22 at 12:54 AM
investornewswire.com logoStrong Sell Recommendations Of Onconova Therapeutics, Inc. (NASDAQ:ONTX) At 0 - Investor Newswire (NASDAQ:ONTX)
www.investornewswire.com - December 17 at 12:45 AM
News IconMy Watchlist for Friday, December 16 (NASDAQ:ONTX)
ac-investor.blogspot.com - December 15 at 7:59 PM
4-traders.com logoONCONOVA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:ONTX)
www.4-traders.com - December 15 at 7:59 PM
biz.yahoo.com logoONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ONTX)
biz.yahoo.com - December 15 at 7:59 PM
News IconThe Jefferies Group Comments on Karyopharm Therapeutics Inc.'s FY2018 Earnings (KPTI) (NASDAQ:ONTX)
mjbstar.com - December 14 at 5:28 AM
News IconShares Plunge to Low Point for the Year: Onconova Therapeutics, Inc. (NASDAQ:ONTX) - Prospect Journal (NASDAQ:ONTX)
prospectjournal.com - December 7 at 9:30 AM
marketexclusive.com logoOnconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Other Events - Market Exclusive (NASDAQ:ONTX)
marketexclusive.com - December 7 at 9:30 AM
nasdaq.com logoComputational Subgroup Analysis of Phase 3 ONTIME Trial Provides Insights into Clinical Response to Rigosertib in Higher-risk MDS (NASDAQ:ONTX)
www.nasdaq.com - December 6 at 9:34 AM
biz.yahoo.com logoONCONOVA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and (NASDAQ:ONTX)
biz.yahoo.com - December 6 at 9:34 AM
finance.yahoo.com logoOnconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual Meeting (NASDAQ:ONTX)
finance.yahoo.com - December 6 at 9:34 AM
marketexclusive.com logoOnconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:ONTX)
marketexclusive.com - December 5 at 9:52 AM
finance.yahoo.com logoOnconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting (NASDAQ:ONTX)
finance.yahoo.com - December 5 at 9:52 AM
finance.yahoo.com logo7:03 am Onconova Therapeutics presents phase 2 data from oral Rigosertib & Azacitidine combination trial in higher-risk myelodysplastic syndromes at 2016 ASH Annual Meeting (NASDAQ:ONTX)
finance.yahoo.com - December 5 at 9:52 AM
investornewswire.com logoBuy Calls Of Onconova Therapeutics, Inc. (NASDAQ:ONTX) At 0 - Investor Newswire (NASDAQ:ONTX)
www.investornewswire.com - December 2 at 12:23 PM
News IconRSI Review on Shares of Onconova Therapeutics Inc. (ONTX) - Yankee Analysts (NASDAQ:ONTX)
yankeeanalysts.com - November 30 at 11:52 AM
News IconStock Focus: Technical Levels in Review for Onconova Therapeutics Inc. (ONTX) - MicroCap Wired (NASDAQ:ONTX)
www.microcapwired.com - November 23 at 6:49 PM
finance.yahoo.com logoONCONOVA THERAPEUTICS, INC. Financials (NASDAQ:ONTX)
finance.yahoo.com - November 23 at 6:49 PM
News IconChecking Moving Average and RSI Levels on Onconova Therapeutics Inc. (ONTX) - MicroCap Wired (NASDAQ:ONTX)
www.microcapwired.com - November 22 at 6:49 PM
News IconTrading Scope: Indicator Review for Onconova Therapeutics Inc. (ONTX) - Yankee Analysts (NASDAQ:ONTX)
yankeeanalysts.com - November 21 at 7:08 PM

Social

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics's stock reverse split on the morning of Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2017?

2 brokers have issued 1 year target prices for Onconova Therapeutics' shares. Their forecasts range from $6.00 to $35.00. On average, they expect Onconova Therapeutics' stock price to reach $20.50 in the next year.

When will Onconova Therapeutics announce their earnings?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

What are analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:

  • According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (4/1/2016)

  • HC Wainwright analysts commented, "Enrollment extends across the pond. Yesterday, Onconova announced that the Phase 3 INSPIRE trial of rigosertib in high-risk myelodysplastic syndromes (MDS) had enrolled its first patient in the EU. We view the news as a positive sign that Onconova remains fully committed to the study, despite the fact that Baxalta (BXLT; not rated) intends to pull out of the program in August. While Baxalta continues to offset trial costs for now, we expect that Onconova will need to re-partner the program or seek another means to fully fund the 225-patient trial, which we estimate could cost $23M to complete. We maintain our conviction that rigosertib has a place in the MDS treatment paradigm, and we see INSPIRE as the main value driver for the company. Additionally, rigosertib has shown compelling evidence of synergy with azacitidine, the current standard-of-care hypomethylating agent (HMA) in a front-line setting, and we expect to hear more about the company’s development plans for the combination later this year." (3/22/2016)

Who owns Onconova Therapeutics stock?

Onconova Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Boxer Capital LLC (4.68%) and Renaissance Technologies LLC (1.82%).

Who sold Onconova Therapeutics stock? Who is selling Onconova Therapeutics stock?

Onconova Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC.

Who bought Onconova Therapeutics stock? Who is buying Onconova Therapeutics stock?

Onconova Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy Onconova Therapeutics stock?

Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Onconova Therapeutics stock cost?

One share of Onconova Therapeutics stock can currently be purchased for approximately $2.81.

Onconova Therapeutics (NASDAQ:ONTX) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Earnings History Chart

Earnings by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Dividend History Chart

Dividend Payments by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Last Updated on 2/23/2017 by MarketBeat.com Staff